Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

may participate in the conference call by dialing (866) 578-5788 or (617) 213-8057, passcode 49255440. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 47807048.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates a
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
(Date:10/27/2014)... 27, 2014 Research and Markets has ... 2014-2018" report to their offering. H1N1 ... a variant of the swine H1N1 virus, known as H1N1v ... nose, throat, and lungs. H1N1 virus is an RNA virus ... animal species such as humans, swine, birds, seals, and horses. ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... Bulletin Board: GOVX ) announced today the publication ... its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety ... Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March ... Diseases . A PDF of the article is available at ...
... Inc., a leader in room temperature biostability technology, ... (IQT). IQT is the independent, strategic investment firm ... mission of the U.S. Intelligence Community. ... pioneered recent innovations in ambient storage of biological ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ( http://www.GreaterTorontoHomeCare.ca ... care, is weighing in on a recent study linking ... performed by the University of Illinois, analyzed 88 patients ... week-long period and observed how much time was spent ... the structural soundness of the white matter in each ...
(Date:10/30/2014)... San Francisco, California (PRWEB) October 30, 2014 ... 5.75 billion by 2020, according to a new study ... consumption, coupled with surging demand for sugar and fat ... expected to augment the demand for prebiotics over the ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... Seattle, WA (PRWEB) October 30, 2014 Sound ... their decision infographic that will assist people any time they ... people discover the right answer by leading them through a ... a resolution to their initial query. , There are many ... or not to use an answering service . This ...
Breaking Medicine News(10 mins):Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... Reporter , WEDNESDAY, Dec. 21 (HealthDay News) -- Problems in ... be at the heart of this learning disorder, new research ... issue of the journal Neuron , may one day ... diagnosed with this common yet still ultimately mysterious condition. ...
... HealthDay Reporter , WEDNESDAY, Dec. 21 (HealthDay ... protein shakes and soup followed by adding low-calorie, high-protein ... which may lessen joint pain and improve their quality ... might also help people whose obesity makes it impossible ...
... Dec. 21 (HealthDay News) -- Ludwig van Beethoven was arguably one ... he was deaf by the end of his career. Now, ... suggests that the progression of his deafness may have shaped his ... Netherlands analyzed three styles of Beethoven,s compositions. In a letter to ...
... induce a rapid weight decline, mainly in the first ... regain, despite continued dieting. The partial regain may ... now shows that improvements to health remain even if ... online in Diabetes Care (Print: February 2012) ...
... 50 per cent more likely to be admitted to hospital ... a study has found. Scots of Indian and Pakistani ... both conditions than people of white Scottish ethnicity. Those ... to hospital with chest pain compared with white Scots, according ...
... beef can contribute to a heart-healthy diet in the same ... DASH diet -- Dietary Approaches to Stop Hypertension -- is ... and reduce risk of heart disease. People following the DASH ... much beef. According to the Centers for Disease Control about ...
Cached Medicine News:Health News:Scientists Probe the Origins of Dyslexia 2Health News:Diet Might Help Those Immobilized by Knee Osteoarthritis 2Health News:Diet Might Help Those Immobilized by Knee Osteoarthritis 3Health News:Did Beethoven's Hearing Loss Shape His Compositions? 2Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 2Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 3Health News:Heart disease study highlights Scottish ethnic groups most at risk 2Health News:Having a cow can be a heart healthy choice 2
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
... or somatomedin C) is a 7.6 kDa peptide ... a potent mitogen of cellular proliferation, exerting its ... the circulation, IGF-I is bound to IGF-binding proteins ... IGF-I by modulating the interaction of IGF-I with ...
... Insulin-like growth factor I (IGF-I or somatomedin ... in the liver. It acts as a potent ... binding to specific cell-surface receptors. In the circulation, ... appear to regulate the actions of IGF-I by ...
... a potent naturally occurring androgen produced ... cholestenone 5a-reductase [1]. The concentrations ... peripheral tissues, including genital skin and ... in apparent association with the nuclear ...
Medicine Products: